论文部分内容阅读
支气管哮喘是一种由多种细胞包括气道的炎性细胞、结构细胞和细胞组分参与的气道慢性炎症性疾病。临床上少数患者通过充分的哮喘治疗包括使用全身性激素治疗后仍不能有效控制,通常称为“难治性哮喘”。免疫反应在难治性哮喘发病机制中起重要作用,而Th1/Th2失衡贯穿于难治性哮喘发病的整个过程。现就难治性哮喘中Th1/Th2失衡机制,以及影响因子(干扰素-γ、白介素-12、白介素-4、白介素-17,白介素-33和转化生长因子-β等)的研究作一综述,以深入探讨难治性哮喘的发病机制。
Bronchial asthma is a chronic inflammatory disease of the airways that is involved in inflammatory cells, structural cells, and cellular components of a variety of cells, including the airways. A small number of clinically ill patients are often referred to as “refractory asthma” by adequate asthma treatment including systemic steroid therapy. Immune response plays an important role in the pathogenesis of refractory asthma, and imbalance of Th1 / Th2 runs through the whole process of refractory asthma. The mechanism of Th1 / Th2 imbalance in refractory asthma and the research on influencing factors (interferon-γ, interleukin-12, interleukin-4, interleukin-17, interleukin-33 and transforming growth factor-β) In order to explore in depth the pathogenesis of refractory asthma.